![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1573, 2007-01, pp. : 15-16
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dasatinib a START-R in imatinib-resistant CML
Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dasatinib off to a good start in imatinib-resistant CML
Inpharma, Vol. 1, Iss. 1523, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dasatinib deals to imatinib-resistant disease
Inpharma, Vol. 1, Iss. 1621, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dasatinib tops imatinib for CML on economic level
Inpharma, Vol. 1, Iss. 1613, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dasatinib tops imatinib for CML on economic level
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 541, 2007-01 ,pp. :